Latest Regulatory Risks News

Boab Metals has obtained Federal environmental approval for its Sorby Hills silver-lead-zinc project, clearing a major hurdle towards development and a final investment decision later this year.

Cauldron Energy has terminated its purchase agreement for river sand leases at Carnarvon and Derby, retaining the Onslow tenements with no further payments required, including cancellation of 2 million shares.

IMEXHS Limited reported steady revenue growth and a strategic push to scale its SaaS medical imaging platform, while navigating margin challenges and regulatory risks in Colombia.

Coast Entertainment Holdings faces a potential regulatory intervention as Queensland's Deputy Premier signals intent to take over assessment of its Dreamworld land development application, citing state economic and environmental interests.

PT Aneka Tambang Tbk (ANTAM) reported a remarkable 240% surge in net profit for the half year ended June 30, 2025, driven by robust gold and nickel sales amid a challenging mining sector.

Perpetual Resources has launched a prospectus to enable trading of new options issued alongside a recent $1.6 million placement, aiming to unlock liquidity while outlining key risks for investors.

Phoslock Environmental Technologies reports a sharp revenue increase driven by Brazil and international markets, yet continues to face significant losses and ongoing legal challenges.

Careteq Limited reported a dramatic reduction in its FY25 loss to just $72,204, down from $2.67 million the prior year, while facing a significant $3.6 million dispute with the Australian Taxation Office over R&D tax claims.

Harvey Norman Holdings Limited reported strong FY25 financial results, driven by growth in franchisee sales, property portfolio appreciation, and digital investments. The company’s integrated retail, franchise, property, and digital system across multiple countries underpins its sustained shareholder returns.

The Star Entertainment Group reported a challenging FY25 with a $471.5 million statutory net loss and a $77.1 million EBITDA loss before significant items, driven by regulatory reforms and market share declines. The group secured a $300 million strategic investment to support its turnaround efforts amid ongoing legal and licensing uncertainties.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

AF Legal Group has reported a record-breaking FY25 with revenue up 27% to $27.6 million and a 77% jump in normalised profit before tax. The firm’s strategic acquisitions and operational improvements set a positive tone for FY26 growth.